Basel, May 31, 2026 – Novartis today announced results showing consistent radiographic progression-free survival (rPFS) improvement across key subgroups with Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan) plus standard of care (SoC; androgen receptor pathway inhibitor [ARPI] + androgen deprivation therapy [ADT]) compared to SoC alone in PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC). These PSMAddition data…
SACRAMENTO, Calif, May 30, 2026 (GLOBE NEWSWIRE) -- Solana Unchained today disclosed the comprehensive operational structure of its upcoming decentralized platform, which unifies artificial intelligence features with three specialized infrastructure protocols. Scheduled to open its initial public allocation phase on May 30, 2026, the ecosystem establishes a functional framework where every internal network service requires…
איסלאמאבאד, May 31, 2026 (GLOBE NEWSWIRE) -- משרד ההסברה והשידור הפקיסטני (MoIB) אחראי על קידום וניהול הנרטיב הרשמי סביב ביקורו של ראש ממשלת פקיסטן שהבז שריף בסין, בציון 75 שנה לכינון היחסים הדיפלומטיים.
NEW YORK, May 30, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Upstart Holdings, Inc. (NASDAQ: UPST) between May 14, 2025 and November 4, 2025, inclusive (the “Class Period”), of the important June 8, 2026 lead plaintiff deadline.
ORION CORPORATION PRESS RELEASE 30 MAY 2026 at 21:30 EEST Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours
